Retatrutide is the next evolution beyond Ozempic, Wegovy, and Mounjaro — safer, better tolerated, and delivering transformative results. Reta MD brings it straight to your door.
Current GLP-1 medications changed the game. Retatrutide is rewriting the rules entirely — a triple-action agonist that targets three receptors instead of one or two.
No waiting rooms. No co-pays. No wasted time. Reta MD brings board-certified physicians directly to you through our secure online platform.
Complete a quick health questionnaire from the comfort of your home. Takes less than 5 minutes.
A board-certified physician reviews your profile and conducts a private virtual consultation.
If medically appropriate, your doctor prescribes Retatrutide — shipped directly and discreetly to you.
Monthly check-ins, dosage management, and 24/7 access to your care team — all online.
Retatrutide is currently in Phase 3 clinical trials, with Phase 2 results published in the New England Journal of Medicine showing unprecedented efficacy.
Retatrutide is the first investigational medication to simultaneously activate GLP-1, GIP, and glucagon receptors — addressing weight loss through three complementary pathways.
In a 48-week Phase 2 trial, participants receiving the highest dose of Retatrutide lost an average of 24.2% of their body weight — surpassing all existing GLP-1 medications.
Eli Lilly's large-scale Phase 3 trials are underway. Reta MD is preparing to be among the first platforms to offer access once FDA approval is granted.
Join the Reta MD waitlist today and be the first to access Retatrutide when it becomes available — no doctor's office, no hassle, delivered to your door.